Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.73 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.73 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.73 |
| ▸ | XDH | P47989 | 6/20 | 0.73 |
| ▸ | FTO | Q9C0B1 | 6/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.73 |
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | APP | P05067 | 6/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.73 |
| ▸ | IPMK | Q8NFU5 | 5/20 | 0.73 |
| ▸ | IP6K2 | Q9UHH9 | 5/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.73 |
| ▸ | RECQL | P46063 | 5/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9288825 | 0.92 | MEN1 (0.78) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| SCHEMBL12378831 | 0.92 | MEN1 (0.78) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| SCHEMBL14254533 | 0.89 | MEN1 (0.58) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| SCHEMBL13056253 | 0.89 | POLH (0.78) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| SCHEMBL18367522 | 0.86 | MEN1 (0.82) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| SCHEMBL8042944 | 0.86 | ABCB1 (0.81) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| Quercetin SCHEMBL27746111 | 0.85 | MEN1 (0.94) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| SCHEMBL7929171 | 0.85 | MEN1 (0.81) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| Quercetin SCHEMBL17629824 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP1A2ABCB1CYP1A1 | |
| Quercetin SCHEMBL31507620 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP1A2ABCB1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7947733-B2 | Phosphorylated pyrone analogs and methods | LIMERICK BIOPHARMA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110028437-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | LIMERICK BIOPHARMA, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | MEN1 4072/4885KMT2A 3401/4885CYP1A2 832/4885 |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MEN1 535/4885KMT2A 4673/4885CYP1A2 817/4885 |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | SLC2A1, SLC2A2, SLC2A3 | MEN1 4409/4885KMT2A 4599/4885CYP1A2 3381/4885 |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | MEN1 2302/4885KMT2A 4512/4885CYP1A2 2311/4885 |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | PC, GLS2, CYP27A1 | MEN1 1731/4885KMT2A 4385/4885CYP1A2 614/4885 |
| US-20110028437-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | MEN1 4072/4885KMT2A 3401/4885CYP1A2 832/4885 |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | MEN1 4072/4885KMT2A 3401/4885CYP1A2 832/4885 |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | MEN1 4072/4885KMT2A 3401/4885CYP1A2 832/4885 |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | MEN1 535/4885KMT2A 4673/4885CYP1A2 817/4885 |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | PGF, ABCG2, PYGB | MEN1 3857/4885KMT2A 4497/4885CYP1A2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.